business backgrounder | industry
“We are really the ‘R’ in research and development.
We get to do the real groundbreaking and exciting
part of the industry in coming up with real solutions
to treat these diseases.”
– Jan Beck, director of research operations for Novo Nordisk
has meant that there has been a lack of major scientific progress in Type 1
diabetes research in recent years.
With the opening of the Seattle research and development center, Novo
Nordisk hopes the expertise they’ve developed in immunotherapy research
will pave the way for significant progress in Type 1
diabetes research.
American Diabetes Association
“ W i t h t h e n e w Ty p e 1
www.diabetes.org
diabetes research and development center, we hope to
Novo Nordisk
accelerate the process of findwww.novonordisk.com
ing new and innovative ways
Washington Biotechnical & Biomedical
of treating people with this
Association
disease,” said Thomsen. “Our
www.washbio.org
vision is to prevent, treat and
ultimately cure diabetes.”
Proud supporter
of the
Association of
Washington
Business
bp.com
spring 2012 35